A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Abroad (travel likely)RecruitingPHASE1
Conditions
Advanced Solid Tumor, Adult · ERBB2 Altered Breast Cancer · ERBB2 Gene Amplification · HER2 Overexpression · Non-Small Cell Lung Cancer · HER2
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
START Midwest, Grand Rapids, Michigan, United States
NYU Langone, New York, New York, United States
Tennessee Oncology, Nashville, Tennessee, United States
NEXT Oncology Texas, Austin, Texas, United States
START Mountain Region, West Valley City, Utah, United States
NEXT Oncology Virginia, Fairfax, Virginia, United States